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Inhibition of HIV-1 entry into its target cells in vitro is a valuable
starting point for both drug and vaccine discovery. The identiﬁcation
of the HIV-1 entry receptor and co-receptors, and derivation of the
crystal structures of various viral envelope (Env) glycoproteins, have
paved the way for the rational development of viral entry inhibitors,
and for design of improved candidate vaccines (Berger et al., 1998;
Feng et al., 1996; Koff, 2010; Kwong et al., 1998; Sattentau et al.,
1993). Productive HIV-1 infection proceeds primarily by CD4
engagement by the Env glycoprotein gp120, followed by engagement
of co-receptor (principally CCR5 or CXCR4), and Env gp41-induced
membrane fusion. The fusion of the viral and target cell membranes is
followed by entry of the viral core into the cytoplasm of the infectedcell (Borkow and Lapidot, 2005; Hartley et al., 2005; Haynes and
Monteﬁori, 2006). However, this process is highly complex and viral
entry kinetics may be dependent upon several parameters inherent in
the in vitro assay chosen.
The Env proteins interact not only with receptor and co-receptor,
but also with other cell surface molecules, including complex lipids
that may be utilized for efﬁcient viral attachment and/or entry
(Haynes and Monteﬁori, 2006). For example, galactosylceramide
(GalCer), a differentiation marker for oligodendrocytes (Gard and
Pfeiffer, 1989), is also found in the vaginal and rectal epithelia, major
sites of initial HIV-1 entry in vivo (Bomsel, 1997; Bomsel and Alfsen,
2003; Bomsel et al., 1998; Fantini et al., 2000). Antibodies directed
against GalCer are able to inhibit viral infection of CD4− cells (Harouse
et al., 1991; Magerus-Chatinet et al., 2007). Peptides from the V3 loop
of gp120 inhibit HIV-1 infection of CD4− cells by adhering to GalCer,
and inhibit infection of CD4+ cells by adhering to the more complex
GSL globotriosyl ceramide (Gb3), or the monosialoganglioside,
hematoside (GM3) (Fantini et al., 1993; Hammache et al., 1998a,
1999, 1998b; Harrison et al., 2010; Nehete et al., 2002). Gb3 and GM3
are major glycosphingolipid constituents of B- (Mangeney et al.,
1991) and T-cell membranes (Degroote, et al., 2004; Delezay et al.,
1996; Sorice et al., 2004), respectively. Of direct relevance to HIV-1
81A. Rosa Borges et al. / Virology 408 (2010) 80–88infection models, mitogen activation of primary PBMC results in
increased expression of GSL, similar to the increased levels of GSL
found on PBMC from HIV-1 positive (but not HIV-1 negative)
individuals (Fantini et al., 1998b; Lund et al., 2006). Interestingly,
levels of Gb3 expression on the surface of PBMC have been shown to
correlate inversely with susceptibility to infection by HIV-1 (Lund
et al., 2009). Taken together, these studies indicate that the
interaction of HIV-1 with complex GSL involves certain surface
determinants that are host cell-speciﬁc.
The observation that aggregated carbohydrate moieties of GSL are
clustered in cell surface lipid rafts or microdomains (Simons and
Ikonen, 1997) and that gp120 binds to glycosphingolipid carbohy-
drate head groups (Kensinger et al., 2004a) suggests that multivalent
carbohydrates (MVC) synthesized using the carbohydrate portions of
Gb3 and GM3 might inhibit the interaction between HIV and the cell
surface and impede viral entry. MVC have been previously used as
molecular mimics for inhibition of a number of host–pathogen and
host–toxin interactions (Schengrund, 2003), but relatively few
studies have been performed using HIV-1 (Kensinger et al., 2004a;
Lund et al., 2006).
Reported here is the synthesis of novel MVC derivatized with the
carbohydrate head groups of either Gb3 or GM3 covalenty attached to
a cationic dendrimer core, and evaluation of their effects on HIV-1
infection of transformed T cells, primary PBMC, and the epithelial
HeLa cell line-derived TZM-bl reporter cells. Potent inhibition of HIV-1
infection of PBMC was observed using MVC derivatized with either
globotriose or 3'-sialyllactose. The MVC also inhibited the membrane
fusion between CD4+ T cells and cells expressing the HIV-1 envelope
protein. The inhibition of HIV-1 primary isolates by novel MVC
suggests that these compounds should be further evaluated as a
potential new class of HIV-1 entry inhibitors.
Results
Synthesis, structure and characterization of MVC
TheMVCwere synthesized by linking the headgroups of either Gb3
(globotriose) or GM3 (3'-sialyllactose) to a highly cationic Gen 5.0Fig. 1. Schematic representation of multivalent carbohydrates (MVC) studied. (A) A two-dim
Concentric circles denote the various dendrimer sizes (the largest being “Gen 5.0”with 64 br
in panel B. (B) Representative structures of 3-(β-D-globotrihexosylthio)propionic acid andpolypropylenimine dendrimer core. A two-dimensional schematic of
the dendrimer is shown in Fig. 1A. The structures of the terminal
globotriose and 3'-sialyllactose moieties linked to the dendrimer core
are shown in Fig. 1B. Table 1 provides details of the characterization of
these compounds; identity of the globotriose oligosaccharide was
veriﬁed by NMR (data not shown). Reaction products weremonitored
for purity and completeness by high performance thin layer
chromatography (HPTLC) (data not shown). The mass and poly-
dispersities of the puriﬁed compounds, and the calculated average
number of carbohydrates per molecule, were obtained using Matrix
Assisted Laser Desorption Ionization Time-of-ﬂight Mass Spectrom-
etry (MALDI-TOF MS) as described previously (Kensinger et al.,
2004b). The MVC used in this study are the two compounds with the
highest number of linked sugars, globotriose 64mer (MVC GBT) and
3’-sialyllactose 64mer (MVC 3SL) (Table 1) with average masses of
35,507 (average of 46 sugars/64mer) and 25,200 (average of 28
sugars/64mer), respectively. Selection of the 64mers for this study
was based upon previous observations that smaller derivatized
dendrimers were less effective at inhibiting HIV laboratory strains
(Kensinger et al., 2004b).
MVC inhibit T cell line infection by T cell line-adapted (TCLA) HIV-1, but
not pseudovirus infection of TZM-bl cells
The ability of MVC to block HIV-1 infection of lymphocytes was
ﬁrst assessed using the CXCR4+ H9 T cell line, a model system that is
typically sensitive for inhibition of HIV-1 CXCR4-utilizing cell line
adapted isolates. BothMVC inhibited infection of H9 cells by three H9-
adapted viruses, with IC50s ranging from 0.2 to 3.6 μg/ml (Table 2). To
further assess inhibition of lymphocyte infection, the A3/R5 T cell line
that was derived from CCR5-transfected, CXCR4+ A3.01 cells
(McLinden et al., in preparation) was employed. Two CCR5-utilizing,
A3/R5 cell line adapted HIV-1 isolates from clades B and D were also
strongly inhibited by the MVC (Table 2). These compounds did not
reduce cell line or PBMC viability or proliferation at concentrations up
to 1 mg/ml (data not shown).
To assess the breadth of MVC activity against multiple strains of
HIV-1 in a model commonly used for both drug development andensional structural diagram of a fully conjugated MVC (from Kensinger et al., 2004b).
anches), terminal spheres represent linked carbohydrates, whose structures are shown
3'-sialyllactose moieties.
Table 1
MALDI TOF MS characterization of multivalent carbohydrates.
Compound Theoretical
Mw (Da)a
Average
Mw (Da)
Polydispersity Average no of
linked sugars
Globotriose 16mer 9363 8084 1.01 11
Globotriose 64mer 43940 35507 1.01 46
3'-Sialyllac 16mer 11808 4967 1.01 5
3'-Sialyllac 64merb 47654 15977 1.02 14
3'-Sialyllac 64merc 47654 25200 1.02 28
a Theoretical Mw (Da) refers to the molecular weight, in daltons, the compound
would have if each arm of the dendrimer were derivatized with the sugar indicated;
Average Mw (Da) is the actual molecular weight, in daltons, determined by MALDI-TOF
MS; Polydispersity gives an indication of the distribution of molecular mass; and the
average no of linked sugars indicates the average number of dendrimer arms
derivatized with the sugar. XXmer indicates the number of available arms on the
polypropylenimine dendrimer.
b An 18-h reaction time.
c A 120-h reaction time.
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luciferase reporter cell line (Mascola et al., 2005; Monteﬁori, 2004;
Wei et al., 2002). Of note, DEAE-dextran (DEAE-dex) is typically used
with pseudoviruses in the TZM-bl assay to enhance virus infection. As
shown in Table 2, neither of the MVC compounds inhibited
pseudovirus infection of TZM-bl cells, up to concentrations of
100 μg/ml. In fact, the compounds displayed differential effects in
this cell line, depending upon the virus stocks utilized in the assay
(data not shown, RosaBorges et al., manuscript in preparation).
MVC inhibit HIV-1 primary isolate infection of PBMC
Given the discrepant results observed in the T cell and epithelial
cell line models, and to test the compounds in a more physiologic
model with CCR5-utilizing viruses, the effects of the MVC on primary
isolate infection of activated PBMCwere studied. The HIV-1 subtype B
91US_US-1 primary isolate, which displays a moderate level of
sensitivity to antibody-mediated neutralization (Brown et al., 2005),
was initially assessed. As can be seen in Fig. 2, both the 3SL (A) and the
GBT (B) MVC inhibited HIV-1 infection in a dose dependent manner.
The possibility of PBMC donor-related target cell variability or
speciﬁcity was addressed by performing replicate assays on PBMC
from three different donors. The downward inﬂection in the curve
(negative inhibition [about −45%] or potential enhancement in viral
growth) seen for 3SL using donors 2 and 3 is within the range of
variation observed in the PBMC inhibition assay.
The inhibition curves and IC50 values observed were relatively
comparable for the three HIV-negative PBMC donors tested (Fig. 2ATable 2
MVC effects on HIV-1 infection using cell line models.
Target cell Viral strain Clade Coreceptor IC50a GBT IC50 3SL
H9 92UG_029 A X4 0.24 0.23
H9 93RW_024 A R5/X4 0.19 0.28
H9 84US_MN B X4 3.6 0.92
A3/R5 85US_BaL B R5 0.1 15.6
A3/R5 99UG_A08483M1 D R5 10.4 3.1
TZM-bl 92UG_029.ec1 A X4 N100 N100
TZM-bl 93RW_024.ec5 A R5/X4 N100 N100
TZM-bl 99KE_KNH1135.ec3 A R5 N100 N100
TZM-bl 84US_MN.ec1 B X4 N100 N100
TZM-bl 92FR_BX08.ec5 B R5 N100 N100
TZM-bl 91US_US-1.ec6 B R5 N100 N100
TZM-bl 01TZ_911.vrca C R5 N100 N100
TZM-bl 02ET_288.vrc38a C R5 N100 N100
TZM-bl 98UG_57128.vrc15 D R5 N100 N100
TZM-bl 93UG_065.ec3 D X4 N100 N100
a 50% inhibitory concentrations (IC50s) presented in μg/ml are the means of at least
two independent assays performed in triplicate (H9 or A3/R5 T cells) or in duplicate
(TZM-bl cells).and B). The breadth and magnitude of MVC inhibition of PBMC
infection was subsequently assessed using 11 HIV-1 primary isolates
(with different co-receptor usages) from subtypes A–D and
CRF01_AE. The MVC IC50s for these isolates in a PBMC assay ranged
from 0.2 to 7.4 μg/ml, as shown in Table 3.
In certain PBMC assay formats, the presence of endotoxin in
samples has been shown to cause an inhibition of HIV-1 infection as
an artifact, with no apparent effects of endotoxin observed in the
TZM-bl assay (Geonnotti et al., 2010). The endotoxin has been
reported to stimulate production of chemokines such as MIP-1-alpha
or -beta, and inhibition of HIV infection may be observed. We
therefore assayed the levels of chemokine production in our PBMC
assay in the presence of MVC to assess any role that chemokines may
play in the inhibition observed. The levels of MIP-1-alpha and -beta in
the supernatants of PBMC cultured for 4 days (the length of the assay)
in the presence of either of the two MVC or LPS was nearly
undetectable (data not shown). The inhibition of HIV-1 in this
PBMC assay thus appears to be attributable to MVC activity and not to
endotoxin-induced chemokines. In support of this inference, the MVC
also inhibited an X4-utilizing virus, as shown in Table 3.
MVC inhibition of HIV-1 envelope-mediated cell fusion
Because GM3 and Gb3 have been implicated in Env-mediated
fusion (Hug et al., 2000; Puri et al., 1998, 1999), we assessed the
effects of the MVC on Env-mediated fusion to begin to dissect the
mechanisms involved in the inhibition of HIV-1 infection by MVC.
HIV-1 fusion was measured between CD8 T cell-depleted PBMC and
the TF228 cells, a B lymphocyte cell line which constitutively
expresses HIV-1 IIIB envelope protein (Jonak et al., 1993). Both MVC
showed N75% inhibition of fusion at 10 μg/ml, a concentration where
potent inhibition was also observed in the PBMC infection assay
(Fig. 3). In the presence of dextran sulfate, the positive control for
inhibition, fusion was blocked completely, while the mock (medium
alone) control showed no inhibition (Fig. 3). These results lead us to
conclude that the mechanism(s) of MVC inhibition of HIV-1 infection
involves the interference of events that lead to gp120-mediated
fusion.
Discussion
In this reportwe have explored the potential use of novelmultivalent
carbohydrate compounds for the inhibition of HIV-1. Our results indicate
that mimetics of the clustered carbohydrates of cell surface GSL involved
in HIV-1 entry can inhibit infection of T cell lines and PBMC by a broad
array of viruses, independent of clade or tropism. While complete
inhibition of fusion was achieved using dextran sulfate, 100% inhibition
was not observed using the twoMVC. This may be indicative of failure of
all cells to express similar numbers of cell surface GSL, or themechanism
of inhibition by the compounds may not be exclusively due to inhibition
of fusion; other factors may play a role in MVC inhibition. It is also
unknown whether or not these compounds may elicit drug-resistant
variants in vivo, as happens with other anti-retrovirals (McKinnell and
Saag, 2009). Future studies in vitrowhere resistant viruses are generated
and then sequenced might reveal the site(s) in the envelope that might
be responsible for development of resistance.
Glycosphingolipids have previously been invoked as key elements
for efﬁcient HIV-1 infection. GM3 and Gb3 are two of the major
glycosphingolipid constituents on major HIV-1-susceptible immune
cells (Degroote, et al., 2004; Delezay et al., 1996; Mangeney et al.,
1991; Sorice et al., 2001). Several lines of evidence suggested that
MVC made from the carbohydrates of these GSL could impact Env-
mediated fusion in vitro. Initial work with neural cell lines deﬁcient in
CD4 highlighted GSL as “alternate receptors” for the HIV-1 (Harouse
et al., 1991). In the case of both T cell lines and primary PBMC, GM3
was closely associated with CD4; the two molecules could be co-
Fig. 2.MVC inhibit infection of PBMC by a primary isolate of HIV-1. Panels A and B show the inhibition of HIV-1 infection byMVC 3SL andMVC GBT, respectively, using the clade B, R5
isolate 91US_US-1. PBMC were isolated from three different donors, as indicated by the square, triangle, and inverted triangle-shaped symbols. Error bars indicate the standard
deviations for three independent experiments.
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2001; Sorice et al., 2000; Yohe et al., 2001). Characterization of gp120
and various glycosphingolipid monolayers or reconstituted mem-
branes indicated that this viral glycoprotein interacts speciﬁcally with
the carbohydrate head groups of both Gb3 and GM3 (Hammache et al.,
2000, 1998a, 1999). While inhibition of synthesis and cell surface
expression of GSL inhibited virus-mediated membrane fusion, the
fusion process was reconstituted upon addition of either puriﬁed Gb3
or GM3 (Hug et al., 2000; Puri et al., 1998, 1999). Furthermore, in
contrast to PBMC from HIV-1 negative donors, lipid membrane
proﬁles of PBMC from HIV-1-infected patients or PBMC stimulated in
vitro with PHA, had increased surface expression of complex GSL,
speciﬁcally Gb3 and GM3 (Fantini et al., 1998a; Lund et al., 2006). Their
role in the perturbation of the host immune system during HIV-1-
associated pathogenesis is indicated by the increased antibody
production against GSL in HIV-1-infected patients (Griggi et al.,
1994; Misasi et al., 1993; Reimer et al., 1988). While induction of
antibodies to GSL represents an altered immune response in the
setting of HIV infection, this may not affect the efﬁcacy of the body to
respond to other immunogens.
The principal of utilizing these GSL and ligand multivalency to
increase avidity of a carbohydrate–protein interaction has been well
demonstrated using GSL and bacterial toxin interactions (Schengrund,
2003). For example, the cell surface receptor for Shiga (Shigella
dysenteriae) and Shiga-like toxins is Gb3. Globotriose headgroups of
this lipid are bound by the toxin, and inhibition in vitro by multivalent
globotriose inhibitors is over a million times more potent than that
observed using monovalent globotriose (Kitov et al., 2000). This
multivalent carbohydrate approach was previously shown to inhibit
HIV-1 infectionusingMVCderivatizedwith sulfated-galactosylmoietiesTable 3
MVC inhibit infection of PBMC by HIV-1 primary isolates from multiple clades.
Viral strain Clade Coreceptor IC50a GBT IC50 3SL
92UG_029 A X4 3.8 1.3
00KE_KER2008 A R5/X4 5.6 2.0
85US_BaL B R5 2.4 2.9
92FR_BX08 B R5 1.7 1.5
91US_US-1. B R5 7.4 3.6
98US_MSC5016 C R5 2.8 1.6
02ET_14 C R5 2.8 2.1
99UG_A08483M1 D R5 0.2 0.5
00UG_D26830M4 D R5 3.1 1.9
90TH_CM244 CRF01_AE R5 2.9 1.6
96TH_NI1046 CRF01_AE R5 5.3 2.3
a IC50s (means of two independent experiments performed in triplicate) are
presented (in μg/ml) for a panel of eleven primary isolates representing ﬁve of the
major clades of the HIV pandemic.(Kensinger et al., 2004a). While the sulfated-galactose MVC inhibited
HIV-1 infection, monovalent sugars did not. A recent study from Lund
et al. (2006) showed effective use of Gb3 micelles as inhibitors of
infection by both CXCR4 and CCR5 viruses, but only clade B laboratory
strains of HIV-1 were tested. Our observation that the globotriose-
derivatizeddendrimers inhibited CCR5 strains agreeswith thoseof Lund
et al. (2006). Hug et al. (2000) found that addition of Gb3 to GSL-
depleted cells markedly enhanced infection by both a CCR5 (BAL) and
CXCR4 strain (IIIB) ofHIVwhile addition ofGM3did so to a lesser extent.
The X4 envelope-mediated fusion studied here was inhibited by both
MVC, as expected. It will be important to test an R5 envelope in a fusion
assay to see if the GBT compound is also effective in this assay. These
future studiesmay also aid in further dissecting themechanismof action
of these compounds. Possible mechanisms to consider include: (1)
gp120 recognizes a structureon theMVCas a ligand, (2) theydisrupt the
lipid raft association of viral binding components needed for formation
of a fusion pore complex (Nguyen et al., 2005), or (3) they block the
interaction of glycosphingolipids present on the virus from functioning
as needed for productive infection (Hatch et al., 2009).
A potential problem with using GSL per se as an inhibitor is the
possibility that they can interact with cell membranes and become
functional receptors. Thiswasﬁrst shown for themonosialoganglioside,
GM1, which serves as a receptor for cholera toxin (Moss et al., 1976),
and a facilitator of HIV-1 infection (Puri et al., 1999). The multivalent
presentation of the Gb3 and GM3 carbohydrate head groups on theMVC
used in these studies reduced their abilities to interact with the cell
surface and provide more HIV-1 binding sites. Our results using these
dendrimeric scaffoldsmirror those of others (Harrison et al., 2010; LundFig. 3. MVC inhibit HIV-1 Env-mediated fusion. Fusion of PBMC with gp120 expressing
cells was assessed by dye transfer in the presence ofMVC 3SL (grey/white checked bar),
MVC GBT (black/white checkered bar), or dextran sulfate (horizontally-hatched bars).
Untreated cells are indicated as themock (white bar). The percent inhibition of fusion is
indicated and error bars indicate standard deviations for ﬁve independent experiments.
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using PBMC was 70 nM, in comparison to N100 μM for their Gb3-lipid
like inhibitors. The increased efﬁcacy (more than 20-fold as calculated
based on the number of sugar molecules present) of our inhibitor may
be due to a greater valency of carbohydrates per molecule, a difference
in size, or possible self-aggregation that could affect potency. Inhibition
of PBMC infection was dependent on pre-incubation of MVC with the
virus (data not shown), suggesting that a direct interactionwith theHIV
envelope is part of the inhibition process.
Tomimic the interactionbetweenHIV-1 clinical isolates andprimary
cells, cell line models are often used by drug or vaccine developers.
HeLa-based (epithelial) reporter cells are commonly used to measure
CCR5 and/or CXCR4 dependent viral entry. Several studies have now
shown divergent neutralizing antibody results between assays using
different cell types (Bagnarelli et al., 2003; Brown et al., 2007, 2008;
Fenyo et al., 2009; Mann et al., 2009; Moody et al., 2010; Polonis et al.,
2008; Polonis et al., 2009; Rusert et al., 2009). Apotential explanation for
the difference in the results in the two cell modelsmay lie in differences
in cell surface coreceptor expression for CCR5. It has been reported that
certain genetically engineered HeLa cell lines have a much higher
expression of cell surface CCR5 than do PBMC from HIV seronegative
donors (Choudhry et al., 2006). Furthermore, the CCR5 surface density
was shown to have an impact on HIV neutralizing antibody efﬁcacy in
that more potent neutralization was observed at lower CCR5 densities.
Data from our laboratory indicate that TZM-bl cells express 1–2 logs
more CCR5 than do either stimulated or unstimulated PBMC from six
independent donors tested (Rosa Borges et al., manuscript in prepara-
tion). Thus our data using the MVC agree with the observations of
Choudhry et al. (2006), as we have observed a lack of HIV inhibition in
the setting of high CCR5 expression. In addition, in a separate study
involving the effects of the CCR5-ligand (and CC-chemokine) RANTES
on HIV-1 infection, it was reported that, while RANTES potently
inhibited infection in most T cell models, varying effects on HIV
infection were seen in non-lymphoid models, including macrophages
and epithelial cells. In fact, RANTES enhanced HIV infection of CCR5-
expressing HeLa cells, and the mechanisms for this enhancement were
proposed to occur via cellular activation by RANTES, as well as by an
increase in viral attachment to cells (Gordon et al., 1999).
Additionally, the host cell that HIV is produced in has an impact on the
levels of HIV inhibition observed in in vitromodels. Interestingly, Louder
et al. (2005) have shown that infectiousmolecular clones (IMC)produced
via 293 T cell transfection are more sensitive to neutralizing antibodies
than thematched IMC stocks after one passage through PBMCdonor cells.
Thus, the HIV envelope topography is clearly distinct and different when
derived from 293 T- versus PBMC hosts (Louder et al., 2005). Our data
with theMVC further highlight the differences observed between viruses
from different sources, as well as differences observed using different
target cells (Table 2, and Rosa Borges et al., in preparation).
In this study, the assessment of MVC inhibition of HIV-1 infection
may depend not only on protein expression but upon membrane
carbohydrate and/or lipid proﬁles, particularly the expression of
complex surface GSL, on the virus envelope and/or the target cell
membrane. These proﬁles are most likely quite different for the
plasma membranes of PBMC versus TZM-bl, and for the envelopes of
pseudoviruses (293 T endothelial cell-derived), as compared with
primary isolates (PBMC-derived). Like PBMC, HeLa-derived cells also
express both Gb3 (Shin et al., 2009) and GM3 (Markwell et al., 1984)
although degree of expression has been shown to vary with degree of
differentiation, passage number, and culture conditions (Markwell
et al., 1984). It is known that mitogen activation increases cell surface
expression of GSL (Fantini et al., 1998a; Lund et al., 2006). T cell
activation was shown to induce lipid raft reorganization (Alonso and
Millan, 2001) and lipid rafts which are enriched in GSL have been
implicated in HIV entry into macrophages (Carter et al., 2009). Gb3
expression on the surface of PBMC has been shown to correlate with
susceptibility to HIV-1 infection (Lund et al., 2009). Combined, theforegoing observations support the hypothesis that differential
membrane GSL proﬁles may be partially responsible for the
differences in the MVC inhibitory capacities in the cell models
employed. These data underscore the importance of the observation
of primary isolate inhibition by the MVC using a primary cell model.
A recent report revealed that endotoxin contamination may
explain some discrepant results between cell line and PBMC-based
assays (Geonnotti et al., 2010). It was therefore essential to evaluate
the role of endotoxin in relation to the MVC results in the PBMC assay.
For several reasons, we conclude that endotoxin effects did not play a
major role in MVC inhibition seen in the PBMC assay used in this
study. The endotoxin mediated HIV-1 inhibition in certain PBMC
assays is thought to occur primarily due to induction of chemokine
expression by monocytic cells (Geonnotti et al., 2010; Verani et al.,
1997). In the PBMC assay employed in these studies, the cells were
ﬁrst stimulated for 4 days with PHA. This procedure typically results
in a loss of more than 90% of the monocytic cells from most PBMC
sources. After PHA stimulation, the CD14+ cells range from 0.1% to
2.4% (as used in this assay) (Brown et al., manuscript in preparation).
With 4-day PHA-stimulation, there appear to be very few cells
available to produce sufﬁcient chemokines in response to endotoxin.
Secondly, the levels of MIP-1-alpha and beta measured in our PBMC
supernatants were below the levels sufﬁcient to mediate the
signiﬁcant HIV inhibitory effects (data not shown) reported by
Geonnotti et al. (2010). Finally, the MVC inhibit X4 viruses, ruling
out inhibition of these viruses by beta-chemokines.
Multivalent approaches utilizing the glycosphingolipid carbohy-
drates globotriose and 3'-sialyllactose suggest a novel, clade-indepen-
dent approach to prevent HIV-1 entry in primary cells. However, the
choice of the cell model system used for in vitro evaluation could have
had a signiﬁcant impact on conclusions regarding the potential utility of
these compounds. These ﬁndings underscore the importance of the
application of different inhibition assessment platforms so that viable
anti-HIV-1 candidates are not overlooked. The identiﬁcation of assay(s)
that can provide in vivo correlates will also be an important element in
thediscovery and development of effective anti-HIVdrugs and vaccines.
Materials and methods
Preparation and characterization of the multivalent carbohydrates
(MVC)
Carbohydrates used, globotriose [Gal(α1–4)Gal(β1–4)Glc] and 3'-
sialyllactose [NeuNAc(α2–3)Gal(β1–4)Glc], were obtained by material
transfer agreements from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Japan)
and NEOSE Technologies, Inc. (Horsham, PA), respectively. Globotriose
was linked to the amino termini of different sizes (generations) of
polypropyleniminedendrimer cores (Sigma-Aldrich, St. Louis,MO) via a
thiopropionic acid spacer arm linked to the C(1)position of the reducing
sugar (Kensinger et al., 2004b). Brieﬂy, globotriose was peracetylated
with anhydrous pyridine and acetic anhydride as described previously
(Wolfrom and Thompson, 1963). The thiopropionic acid globotriose
derivative was prepared from peracetylated globotriose by incubation
with a ﬁve-fold molar excess of 3-mercaptopropionic acid (Sigma-
Aldrich, St. Louis, MO) and borontriﬂuoride diethyletherate (Sigma-
Aldrich) in anyhdrous dichloromethane (Elofsson, et al., 1991;
Magnusson et al., 1981). High performance thin layer chromatography
(HPTLC) (VWR Scientiﬁc Products, Westchester, PA) was used to
monitor completeness of the reaction andpurity of the isolatedproducts
(solvent–butanol: methanol: water, 2:1:1, v:v:v). The product was
characterized by NMR after deacetylation using methanolic sodium
methoxide (Zemplen, 1926).
Peracetylated 3-(β-D-globotrihexosylthio)propionic acid was
coupled to a polypropylenimine dendrimer core using O-(7-Azaben-
zotriazol-1-yl)-N,N,N',N',-tetramethyluronium hexaﬂuorophosphate
(HATU) and diisopropylethylamine to activate the carboxyl group
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to 1.5 equivalents per terminal amine on the dendrimer core was
resuspended in acetonitrile to which one equivalent each of HATU
(Sigma-Aldrich) and diisopropylethylamine (Sigma-Aldrich) were
added. Dendrimer core, dried from dichloromethane under nitrogen,
was added dropwise while stirring. After adjusting the solvent to a 1:1
(v:v) ratio of dichloromethane:acetonitrile, the reaction was stirred
overnight at room temperature. Product formation was monitored by
the presence of derivatized dendrimer at the origin after HPTLC
(solvent–butanol:methanol:water, 2:1:1, v:v:v) (data not shown).
Carbohydrate containing compounds were visualized using 5% sulfuric
acid in ethanol. When the reactionwas complete, the sample was dried
and deacetylated (Zemplen, 1926). Puriﬁed derivatized dendrimer was
obtained by chromatography on BioGel P2 (Biorad, Hercules, CA) using
1 M pyridine acetate (pH 5.5) as eluant.
The presence of the carboxyl group on the sialosyl residue on 3'-
sialyllactose precluded use of the samemethod to link it to the primary
amines on the dendrimer. Therefore, reductive amination was used as
the coupling method (Gray, 1978). Two mole equivalents of 3'-
sialyllactose per amino terminal on the dendrimer core were resus-
pended in 0.2 Mborate buffer, pH 10.5, prior to the addition of onemole
equivalent of dendrimer amines. Sodium cyanoborohydride was then
added with stirring and the reaction incubated at 37 °C for up to 120 h.
Product was puriﬁed by chromatography on a BioGel P2 column as
described above. Fractions containing carbohydrate-derivatized den-
drimer were pooled, taken up in a small amount of water and then
centrifuged through a 3 kDa molecular weight cut-off ﬁlter to remove
residual low molecular weight materials (including unreacted 3'-
sialyllactose). Matrix Assisted Laser Desorption Ionization Time-of-
FlightMass Spectrometry (MALDI-TOFMS)was used to characterize the
carbohydrate-derivatized dendrimers. Analyses were done using a
Perspective Biosystems Voyager DE-PRO spectrometer (Perspective
Biosystems, Foster City, CA). 100–200 sample spectrawere generated in
a linear positive ion mode using a trans-3-indoacrylic acid (IAA) (Acros
Organic, Pittsburgh, PA)matrix (20 mg/ml in dimethylformamide) that
was diluted 10:1 by the addition of 1–10 mM aqueous solution of
sample. This gave a working ratio of IAA to analyte of about 1000:1
(Kensinger et al., 2004b; Woller and Cloninger, 2001). Average
molecular weights and polydispersities of the dendrimers were
calculated using DataExplorer software, version 4.0 (Applied Biosys-
tems, Foster City, CA). The average number of carbohydrate units
conjugated to a dendrimer core was calculated by subtracting the
theoretical MW of the native, underivatized dendrimer core from the
MW of the corresponding derivatized dendrimer and dividing the
difference by the weight of the attached sugar moiety minus 18 Da for
the water molecule displaced during formation of multivalent globo-
triose and 16 Da during addition of sialyllactose using reductive
amination. NMR spectra for the thiopropionic acid derivative of
globotriose [3-(β-D-globotrihexosylthio)propionic acid] were obtained
using a Bruker DRX-400NMRoperating in the quadraturemode at 25 °C
using a triple-axis-gradient broadband inverse probe as previously
described (Kensinger et al., 2004b).
Titration of primary HIV-1 isolates
Donor PBMC were obtained by leukophoresis of blood from HIV-
1-negative donors (BRT Laboratories, Inc, Baltimore, MD); PBMC
were isolated by Ficoll-Hypaque density gradient centrifugation and
cryopreserved. All incubations were in a 95% humidiﬁed–5% CO2
environment. Viral titrations were set up by serially diluting samples
for all cell line assays with cRPMI [RPMI 1640 (Quality Biologics,
Gaithersburg, MD) containing 100 U/ml penicillin (Quality Biolo-
gics), 100 μg/ml streptomycin (Quality Biologics), 2 mM L-glutamine
(Quality Biologics), 15% fetal calf serum (FCS) (Gemini-Bio, Wood-
land, CA)] or for PBMC with cRPMI/IL-2 medium [cRPMI supple-
mented with 20 U/ml of recombinant IL-2]. Titrations wereperformed in quadruplicate wells in 96-well microtiter plates,
using an equal amount of medium or normal human serum (NHS)
(Gemini-Bio, Woodland, CA) without inhibitors. Virus was incubated
for 30 min in medium at 37 °C and then 50 μl aliquots containing
1.5×105 PHA (DIFCO, Detroit, MI/Roche, Indianapolis, IN)-activated
PBMC or 1×105 T cells were added to each well for infection
overnight at 37 °C. Plates were washed three times with media to
remove excess virus and cells were transferred to a round-bottom,
96-well plate. On days 4, 6, and 8 post-infection, 100 μl of medium
were harvested and an equal volume of new medium was added
back. On days 4, 6, and 8, p24 was quantiﬁed using an antigen
capture assay (Beckman Coulter, Miami, FL); sample wells with a p24
concentration N60 pg/ml were scored positive. An endpoint virus
titer, or 50% tissue culture infectious dose (TCID50), was calculated
for day 8 by the Spearman–Karber method (DAIDS, 1997). The
nearest dilution of virus that yielded N10 ng/ml of p24 in control
wells by day 4 or day 6 was used in inhibition assays.HIV-1 inhibition assay using T cell lines or PBMC
These assays were performed in triplicate for each virus/inhibitor
combination, including 8 control wells of virus and cells only, in 96-
well deep-bottom (0.5 ml) plates. A dilution of virus stock yielding
N10 ng/ml of p24 at day 4–6 in previous titrations (on the relevant
cell type) was used. After 30 min pre-incubation of virus (25 μl) and
test reagent (25 μl) at 37 °C, a 50-μl aliquot containing either 1.5×105
PHA/IL-2 PBMC or 1×105 H9 or 1×105 A3/R5 [T cell line engineered
to over express CCR5 (R McLinden, unpublished results)] was added
to each well. Cells were infected for 18–20 h and then washed twice.
After a third wash, cells were resuspended in 250 μl of appropriate
growth medium and transferred to 96-well U-bottom plates. On days
4, 6 and 8, 100 μl of supernatant was harvested for p24 analysis, and
replaced with 100 μl of growth medium. When p24 levels in the virus
controls were above 10 ng/ml, pooled triplicate supernatants were
tested for p24. The percent inhibition was calculated by the percent
reduction of p24 production at day 4 or 6, depending on viral growth
kinetics. Infection of H9 cells was tested using three H9-adapted
viruses: 92UG_029/H9 (clade A, X4), 93RW_024/H9 (clade A, dual
tropic), and MN (clade B). Infection of A3/R5 cells was assayed with
A3R5-adapted A08483M1/A3R5 (clade D, R5) and BaL/A3R5 (clade B,
R5) viruses (Table 2), and PBMC were tested using a panel of primary
isolates (Table 3). Dextran sulfate was used as a control for viral fusion
and a neutralizing HIV+ pooled serum collected from HIV+ subtype B
patients under informed consent through an IRB approved protocol
was used as an assay control for viral inhibition. Percent inhibition
was plotted vs. concentration of MVC, and IC50s were calculated using
a quadratic projection based program (Mascola, 1999).Cell viability assay
Effect of MVC on cell viability was assessed bymonitoring activity of
mitochondrial deyhydrogenases as described in the ATCC cell viability
protocol (http://www.atcc.org/common/documents/pdf/30-1010k.
pdf). In brief, cells, seeded in deep-well or standard 96-well plates,
respectively, were grown in medium alone (control wells), or in the
presence of serially diluted MVC, and incubated at 37 °C. After
incubation for 24 h, medium was removed and the cells washed with
PBS, (and in the case of PBMC, transferred to a clear bottom 96-well
standard plate) and then co-incubatedwithMTT reagent in the dark for
30 min; the A490 was read on an ELISA plate reader. The percent viable
cells was calculated by:
1− A490 untreated cells−A490 treated cellsð Þ = A490 untreated cellsð Þ½  × 100
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Pseudoviruses were prepared by transfecting 5×106 exponentially
dividing 293 T cells in 20 ml growth medium (DMEM) in a T-75
culture ﬂask with 8 μg of env expression plasmid and 24 μg of an env-
deﬁcient HIV-1 backbone vector (pSG3ΔEnv) using FuGene as the
transfection reagent (Roche, Indianapolis, IN). Pseudovirus-contain-
ing culture supernatants were harvested 3 days after transfection,
centrifuged and stored at −80 °C in 1 ml aliquots. TCID50 measure-
ments were done in triplicate using 8 serial four-fold dilutions of each
pseudovirus. For each dilution, 100 μl were placed in a 96-well culture
plate and trypsinized TZM-bl cells (10,000 cells in 100 μl of growth
medium) were added to each well. Plates were incubated at 37 °C in a
5% CO2 incubator with 95% humidity for 48 h. To measure luciferase
activity, the culture medium was removed, the monolayers were
washed once with PBS, and a 20 μl aliqout of lysis buffer (Promega
Corp, Madison, WI) was added to the cells. Plates were subjected to
two freeze/thaw cycles to lyse cells, and 100 μl of reconstituted
Luciferase Assay Substrate (Promega Corp) was then added to each
well and luminescence was measured using a Victor 2 luminometer
(Perkin-Elmer Life Sciences, Shelton, CT). Wells producing relative
light units (RLU) N2.5× backgroundwells (containing cells only) were
scored positive for infection. An endpoint virus titer, or TCID50 was
calculated by the Spearman–Karber method (DAIDS, 1997). Ten
pseudoviruses presented in this study were prepared with env clones
from a panel of primary viruses (Brown et al., 2005). The
pseudoviruses represent four of the major clades of the HIV pandemic
and are coded by year of isolation, country of origin and strain
identiﬁcation as follows: clade A: 99KE_KNH1135.ec3, 92UG_029.ec1,
93RW_024.ec5; clade B: 84US_MNp.ec1, 92FR_BXO8.ec5, 91US_1.ec6;
clade C: 02ET_288.vrc38a, 01TZ_911.vrca; clade D: 98UG_57128.
vrc15, 93UG_065.ec3.
Reporter cell line infectivity assay
Each pseudovirus was incubated with various dilutions of 0.22 μm
ﬁlter sterilized MVC in duplicate for 1 h at 37 °C in a total volume of
50 μl DMEM in 96-well ﬂat-bottom culture plates (Corning-Costar,
Corning, NY). Pseudovirus infection assays were conducted in the
absence of DEAE-dextran to avoid any interference with virus–
dendrimer interactions. Trypsinized TZM-bl cells (104) were then
added in 50 μl of growth medium. Six wells contained cells and virus
(virus control), and another six wells contained cells only (back-
ground control). After 48 h, luciferase activity was quantiﬁed, as
described above. The IC50 was calculated as the concentration of
sample that reduced RLU by 50% compared to that obtained in the
virus-only control, after subtraction of background RLU.
HIV Env-mediated fusion assay
Fusion was measured by quantiﬁcation of syncytium formation
between PHA-activated, CD8 T cell-depleted PBMC and TF228 B cells,
as described previously (Puri et al., 1999). The target cells, PHA-
stimulated PBMC(CD8−), were labeled with CMFDA, a green
ﬂuorescent marker (Ex/Em 492/517, Molecular Probes, Junction
City, OR). The effector cells expressing HIV env TF228, were labeled
with CMRA, an orange ﬂuorescent marker (Ex/Em 548/576, Molec-
ular Probes). Both target and effector cells were labeled in serum-free
media containing probe at a concentration of 1 μg/ml; cells were
incubated at a density of 106 cells/ml for 1 h at 37 °C. Labeling media
was then removed and cells washed twice with PBS, suspended in IL-2
containing RPMI-10 media, and further incubated at 37 °C for 30 min.
Cells were then centrifuged and resuspended in cRPMI/IL-2 medium;
PBMCwere at 6×106 cell/ml and TF228 cells were at 2×106 cells/ml.
To score fusion, these cells were co-cultured (50 μl of each cell type) in
a ﬂat bottom 96-well plate at a 3:1 ratio (PBMC to TF228 cells). Cellswere allowed to undergo fusion for 4 to 6 h in the presence of MVC,
medium only (negative control), or dextran sulfate (positive control).
Five replicate images were captured for each well on a Nikon
ﬂuorescent microscope using a 20× objective lens. Fusion events
were scored as syncytia that were positive for both CMFDA and CMRA
markers. Percent fusion was calculated by dividing the number of
double-positive cells by the total number of target cells (positive for
green dye only). Results are presented as themean of all ﬁve images±
standard deviation. Fusion was normalized to 100% of control, media
only wells.
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